Actionable news
All posts from Actionable news
Actionable news in SCMP: Sucampo Pharmaceuticals, Inc.,

Sucampo (SCMP) Remains Focused on Amitza Label Expansion

We issued an updated report on Sucampo Pharmaceuticals, Inc. SCMP on July 4.

Rockville, MD-based Sucampo Pharmaceuticals is a global biopharmaceutical company which currently has one marketed product, Amitiza, in its portfolio. Amitiza is approved for chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) among adult women and opioid-induced constipation (OIC) in patients with chronic non-cancer pain.

Sucampo has a license, commercialization and supply agreement with Mylan MYL for marketing Amitiza in Japan, where it is approved for chronic constipation (CC), except constipation caused by organic diseases. Japanese pharma company Takeda, which holds global marketing rights for Amitiza outside Japan and China, continues to work on launching...